Llew Keltner ? Battling solid tumours with light Pharmaceutical Technology Europe, UK - Current cancer treatments ?surgery, radiation therapy, chemotherapy, and other local ablative therapies ? have significant shortcomings, such as severe ...
Erbitux gets extended European approval Hays Pharma, UK - The company said patients given Erbitux in addition to a standard first-line platinum-based chemotherapy lived significantly longer than those patients who ...
Health Buzz: New Flu Vaccines and Other Health News U.S. News & World Report, DC - ... told Kotz how she prepared herself in advance for the sexual difficulties that often follow a disfiguring mastectomy, fatiguing chemotherapy , and drugs...
How Chemo Kills Tumors: Research To Reduce Side Effects Science Daily (press release) - 6, 2008) ? University of Manchester researchers are investigating exactly how chemotherapy drugs kill cancerous tumours in a bid to reduce side effects and ...
THC-like drug aids prevention of colon cancer UT The Daily Texan, TX - Aug 5, 2008 ...chemotherapy and other cancer treatments, DuBois said its preventative capabilities went unnoticed because a receptor absent in patients with advanced...
Other News To Note TMCnet - The firm said that the proposed clinical plan is in direct response to current studies indicating tumors resistance to chemotherapy and radiation are linked ...
OXiGENE Reports Second Quarter 2008 Results MarketWatch - Aug 3, 2008 At the 2008 ASCO meeting, the company reported data from an ongoing Phase I study of vascular disrupting agent OXi4503 in patients with advanced solid ...
Combination chemotherapy in the treatment of advanced Hodgkin's disease. VT Devita Jr, AA Serpick, PP Carbone - Ann Intern Med, 1970 - ncbi.nlm.nih.gov Combination chemotherapy in the treatment of advanced Hodgkin's disease ... Adult; Aged;
Antineoplastic Agents/therapeutic use*; Bone Neoplasms/drug therapy; ...
… Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma - MR Middleton, JJ Grob, N Aaronson, G Fierlbeck, W … - Journal of Clinical Oncology, 2000 - jco.ascopubs.org ... Phase I study of temozolomide in paediatric patients with advanced cancer ... Kemppinen
M, Muhonen T: A promising interferon plus four-drugchemotherapy regimen for ...
Metronomic chemotherapy plus antiangiogenesis drug has activity in advanced breast cancer
Chemotherapy given in low, frequent doses – a novel strategy called "metronomic" delivery – achieved partial shrinkage of disease in some advanced breast cancer patients when given concurrently with an angiogenesis inhibitor.
In a pilot study of 55 patients, the combination of low-dose chemotherapy and the anti-VEGF antibody, Bevacizumab ( Avastin ) delayed the breast cancer's progression by an average of 5 ½ months, compared to two months with the low-dose chemotherapy alone, said Harold Burstein, at Dana-Farber.
" Pairing metronomic therapy with a dedicated angiogenesis inhibitor showed clinical activity, and was quite well tolerated," said Burstein. "We think this is a combination worth pursuing and are exploring this treatment concept further in a Phase II study, which extends these treatments into early stage breast cancer therapy."
The current study is one of the first rigorous tests of a treatment strategy that was proposed several years ago as a means of improving the results of chemotherapy for breast cancer, said Burstein.
Historically, high doses of chemotherapy are given at intervals of two to three weeks, with time off the drug to recover from side effects. However, laboratory researchers have suggested that this rest period also allows the blood vessels feeding the tumor to re-form after they had been destroyed by the chemotherapy. They proposed giving smaller, almost constant doses of the drug – as regular as the ticking of a metronome – as a way to hamper angiogenesis.
In the Dana-Farber study, the chemotherapy drugs Cyclophosphamide and Methotrexate were given in a metronomic regimen to 21 patients with advanced, metastatic breast cancer.
In another 34 patients, the chemotherapy was paired with the angiogenesis inhibitor Bevacizumab given intravenously every 14 days. None of the patients had been previously heavily treated for their advanced cancer.
The metronomic-alone therapy led to two partial responses ( 10 percent of the patients ), while in another eight patients the cancer remained stable. Results seemed better in the combination group, in which 10 patients ( 29 percent ) had partial responses, while 14 ( 41 percent ) experienced stable disease.
There were still some side effects in both groups, including fatigue, but Burstein said the therapies were generally well tolerated and lacked the major side effects of traditional chemotherapy such as gastrointestinal and hair loss.
The researchers concluded that the metronomic therapy by itself had limited clinical activity, but the activity seen when the anti-angiogenesis drug was added suggests "further investigation of this novel treatment study is warranted."
